Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have identified a signaling pathway regulating macropinocytosis in pancreatic tumors, which could lead to personalized treatments. The study reveals that tumors can dynamically adjust their nutrient uptake, with some 'dialing up' or 'dialing down' macropinocytosis based on glutamine availability.
Researchers discovered that CA19-9, a complex sugar molecule, causes pancreatitis by recruiting the immune system and inducing deleterious biochemical reactions. Targeting CA19-9 with antibodies may prevent or treat pancreatitis and its progression to pancreatic cancer.
A widely recognized biomarker, CA19-9, is found to promote the development of pancreatic diseases and cancer in genetically engineered mice models. This discovery suggests new treatment strategies for pancreatic cancer and other cancer biomarkers.
Researchers found that FOLFIRINOX prolonged patients' lives by an average of 22.2 months, increasing the chances of complete tumor removal through surgery. More than two-thirds of cancers responded well to treatment, allowing for surgical removal.
Researchers have identified a new type of fibroblast in pancreatic cancer tumors that can evade immune detection. The discovery, published in Cancer Discovery, highlights the complex role of these cells in protecting cancer cells and could lead to new therapeutic strategies.
Researchers from the University of Oklahoma College of Medicine have identified ZIP4 as the trigger for muscle-wasting cachexia in pancreatic cancer. By inhibiting ZIP4, they hope to prevent cachexia and improve treatment outcomes for patients with pancreatic cancer.
A new pilot study demonstrated the feasibility of using molecular tumor markers to guide chemotherapy selection in patients with metastatic pancreatic cancer. The study reported promising progression-free survival and overall survival rates, with partial responses seen in 28% of patients.
Researchers have identified a biomarker that can accurately predict which pancreatic cysts are likely to become cancerous, offering new hope for improved diagnosis and treatment. The biomarker, mAb Das-1, was found to be more accurate than current methods in predicting cancer risk, with a accuracy rate of 95%.
A recent study by USC researchers found that Native Hawaiians have a 60% increased risk of pancreatic cancer compared to European Americans. The study also revealed that Japanese Americans and African Americans are at a higher risk than previously thought, with increases of 33% and 20%, respectively.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
A study found that pancreatic cancer cells can behave differently based on their surroundings, with some responding better to chemotherapy and radiation. The stroma of tumors consists of connective tissue cells that contribute to tumor growth and spread.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
Seven cutting-edge research projects have been awarded grants to tackle pancreatic cancer, with a focus on early diagnosis, potential new treatments, and understanding immunotherapy's limitations.
A new study found that one-third of patients with metastatic pancreatic cancer do not see a medical oncologist, and even more do not receive cancer-directed treatment. The data suggest that there are many missed opportunities for important discussions between patients and cancer specialists.
Eight researchers from the University of Texas M. D. Anderson Cancer Center have been awarded $100,000 fellowships to conduct high-impact cancer research over two years. The Andrew Sabin Family Fellowship Program aims to encourage creativity and innovation in cancer research.
Researchers found that removing the ATDC gene from pancreatic cells prevented the development of pancreatic cancer in mice. The study identified ATDC as a key player in the reprogramming of adult cells into primitive, high-growth cell types, which can lead to cancer.
In a mouse model of unresectable pancreatic cancer, administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival. The study found that FG-4592 effectively mimicked hypoxia in normal tissues, protecting them from radiation damage.
Researchers found that the interaction between pancreatic stellate cells and cancer cells could be exploited due to high levels of LIF, a key protein responsible for activating PSCs in cancer cells. Elevated LIF levels correlate with disease progression and chemotherapy resistance.
Researchers at Salk Institute uncover role of signaling protein LIF in pancreatic cancer development and progression, suggesting it may be a useful biomarker for earlier diagnosis and more effective therapies. Elevated LIF levels were significantly correlated with tumor cell status and response to chemotherapy.
A new diagnostic method for pancreatic cancer has been developed by researchers at the University of Copenhagen, utilizing circular DNA to identify cancer cells in blood tests. The technology is expected to classify cancer cells in individual patients and implement personalized treatment regimens, leading to increased survival rates.
Researchers from CNIO have successfully removed advanced pancreatic ductal adenocarcinoma (PDA) in animal models through combined inhibition of EGFR and c-RAF kinase. This breakthrough has shown significant promise for developing new cancer treatments.
Researchers have identified a key hormone receptor called RORγ that promotes tumor growth and is responsible for therapy resistance in pancreatic cancer. Blocking this receptor slows patient-derived tumor growth and improves survival in animal models, providing new avenues for research and potential therapies.
A subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer showed sustained clinical responses to rucaparib, a PARP inhibitor. The treatment provided complete or partial responses and reduced tumor size in some instances.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
Researchers found that rucaparib reduced tumor size and controlled growth in 17 out of 19 patients with BRCA1, BRCA2, or PALB2 mutations. The study provides promising early evidence for this approach as a less toxic option.
A study found that excess body weight before age 50 is strongly associated with an increased risk of dying from pancreatic cancer. The research, which analyzed data from over 963,000 adults, suggests that excess weight measured earlier in adulthood may be more closely linked to pancreatic cancer risk than previously thought.
A new combination of immunotherapy and chemotherapy has caused tumors to shrink in 83% of patients with metastatic pancreatic cancer. The treatment, involving a CD40 antibody, checkpoint inhibitor, and standard-of-care chemotherapy, showed manageable side effects, suggesting a durable response.
African American women with poor oral health may face a substantially increased risk of developing pancreatic cancer. Researchers found that adult tooth loss and periodontal disease prevalence were associated with a higher risk, particularly among those who had lost at least five teeth.
The Pancreatic Cancer Collective has awarded two million-dollar grants to AI teams developing tools to identify high-risk individuals with pancreatic cancer. One team will focus on rare gene variants and the other on machine learning analysis of clinical records and images.
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Researchers established two human pancreatic cancer cell sublines with high metastasis potential, MIA PaCa-2 In8 and Panc-1 In8, which demonstrated increased migration, invasion, and clonogenic abilities compared to their parental cells. The study also identified a dysregulated lncRNA-miRNA-mRNA competitive endogenous RNAs (ceRNAs) net...
A study published in Nature identified a new approach to starve pancreatic cancer cells of molecular resources. The researchers found that the protein syndecan-1 plays a critical role in regulating macropinocytosis, a mechanism used by cancer cells to scavenge resources and divide.
Researchers found that tumor-associated macrophages release compounds that block the action of gemcitabine in malignant cells. The study suggests that patients with fewer macrophages in their tumors may respond better to chemotherapy. This discovery could lead to new approaches for treatment.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.
A recent study found that high levels of the 'proofreading' enzyme PHLPP1 lead to low PKC levels in pancreatic cancer patients, associated with poor prognosis. The researchers aim to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC to improve survival rates.
Researchers at GW Cancer Center discovered USP15 as a potential biomarker for treatments of breast and pancreatic cancers. The enzyme regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Researchers found that oral bacteria are associated with the severity of cystic pancreatic tumours, which can become cancerous. The study suggests that certain oral bacteria may play a role in the development of pancreatic cancer.
Researchers have discovered a combination drug therapy that may effectively combat pancreatic cancer. The Pancreatic Cancer Collective, led by Martin McMahon and David Tuveson, has received funding to support clinical trials of the new treatment.
Researchers at UPMC and the University of Pittsburgh School of Medicine discovered genetic flags in 17% of tumors indicating susceptibility to existing chemotherapy drugs. The study's findings could lead to personalized treatment approaches for pancreatic cancer patients, increasing survival rates.
Researchers at UNC Lineberger Comprehensive Cancer Center have made a promising discovery in treating pancreatic cancer by making cells reliant on autophagy, a process of cellular recycling. A novel treatment strategy combining an autophagy inhibitor with another compound has shown increased efficacy in laboratory studies.
Researchers at Huntsman Cancer Institute discovered a combination drug therapy that may effectively combat the disease. The study, led by Conan Kinsey and Martin McMahon, found a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.
A retrospective study found that inherited mutations in pancreatic cancer susceptibility genes may increase the risk of developing pancreatic cancer in patients with specific precursor lesions. The study analyzed DNA from 315 patients and found a higher likelihood of invasive pancreatic cancer in those with inherited mutations.
Researchers identified a gene called UCP-1 that may predict the development of pancreatic cancer in people with Type 2 diabetes. The study found three distinct metabolic phases prior to diagnosis, characterized by rising blood glucose levels and changes in body fat.
Researchers have identified at least four different types of scar tissue in human pancreatic cancer, each influencing the disease in a unique way. This discovery may lead to tailor-made treatments, including immunotherapies, that target the powerful scar tissue wall protecting the cancer.
Cancer rates linked to obesity are rising faster in US young adults compared to older generations. Incidence of certain cancer types such as colorectal, uterine corpus, and pancreatic cancer has increased significantly in younger age groups.
A new 3D imaging technique has revealed that pancreatic cancers can develop in two distinct types - 'endophytic' and 'exophytic' - depending on the size of the duct. This breakthrough may lead to improved treatments for pancreatic cancers by better understanding how cancer grows.
Researchers found distinct bacteria on the tongue of early-stage pancreatic cancer patients compared to healthy individuals. The study suggests a potential link between the immune system and pancreatic cancer, paving the way for new diagnostic or preventive tools.
A new recovery pathway has been implemented to reduce hospital stays after the Whipple operation by 15 days, allowing patients with pancreatic cancer to transition more quickly to the next phase of treatment. The study found that this accelerated care did not increase complication rates and improved patient outcomes.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
A new combination blood test has been developed to detect pancreatic cancer earlier, with a detection rate of nearly 70% and a false-positive rate of less than 5%. The test uses two different sugars produced by pancreatic cancer cells and can detect subtypes that may have been missed by existing tests.
Researchers identified VISTA on immune cells infiltrating pancreatic tumors, which resisted immune checkpoint blockade drugs. The study highlights the importance of stroma and found higher expression of VISTA in pancreatic tumors compared to melanoma.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
A phase I/II trial found that combining nab-paclitaxel with gemcitabine significantly improved survival rates even among patients with reduced health status. The study's results suggest alternative treatment options for patients typically underrepresented in clinical trials.
The Pancreatic Cancer Collective has awarded $7 million in grants to seven teams of top cancer researchers. The funding will support clinical studies and accelerate the translation of research findings into treatments, with the goal of improving patient outcomes for pancreatic cancer.
A team of UC San Diego researchers has received a $1 million Stand Up To Cancer grant to test drugs that block signals driving pancreatic cancer growth. The study aims to identify new therapies that can more effectively block tumor growth and metastasis.
Researchers have discovered a new compound, ancistrolikokine E3, from a Congolese rainforest vine that effectively targets and kills pancreatic cancer cells. The compound inhibits the Akt/mTOR pathway and autophagy pathway, leading to dramatic changes in cell morphology and preventing metastasis formation.
Researchers have identified a compound, ancistrolikokine E3, from the twigs of the Ancistrocladus likoko vine that kills pancreatic cancer cells when nutrients are scarce. The compound inhibits the Akt/mTOR pathway, which is responsible for the aggressive proliferation of these cancer cells.
Researchers identified TP63 as the culprit behind aggressive pancreatic cancer's addictive behavior. Suppressing its activity could lead to a tumor's demise. The study aims to understand why TP63 gets active in some patients' pancreas, with the goal of developing a treatment to improve their survival.